Pharmaceutical Technology

MAY 23, 2023

BioCryst Pharmaceuticals has secured marketing authorisation from the Public Health Institute (ISP) of Chile for oral, once-daily ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) attacks in patients aged 12 years and above.

Marketing 52

Marketing Biopharma Safety Pharma 52

Clarivate

NOVEMBER 10, 2022

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. Patient focused drug development in alopecia areata clinical trials.

Patients 52

Patients Food and Drug Administration FDA Safety 52

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Sales 108

Sales Biopharma Medicine Patients 108

European Pharmaceutical Review

NOVEMBER 16, 2022

Engineering or redesigning facilities without due consideration of what is needed, of what may be superfluous, or of how systems and processes will be validated over time, could lead to costly remedial action and delays in getting important and premium new products to market. Embracing the spirit rather than the letter of regulations.

Manufacturing 109

Manufacturing Pharma Biopharma Management 109

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. Evaluate’s VC data show quarter-over-quarter drops in the number of biopharma companies raising private cash and in the amount of money raised.

Biopharma 111

Biopharma Pharma Marketing Management 111

pharmaphorum

JULY 4, 2022

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS), although its share price remains under pressure. Some children are born with an abnormally short small intestine.

Biopharma 92

Biopharma Leads Food Safety 92

European Pharmaceutical Review

JUNE 13, 2023

Novartis has entered into an acquisition agreement with biopharma Chinook Therapeutics for a value up to £2.5 According to the CEO of Novartis, Dr Vas Narasimhan, the company is excited by the potential for bringing “additional much-needed treatment options to patients”. These immune complexes trigger inflammation and kidney damage.

Biopharma 52

Biopharma Safety Leads Pharmaceutical 52

pharmaphorum

JANUARY 6, 2023

a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which develops therapies for autoimmune and inflammatory diseases – in an all-stock transaction. ACELYRIN, Inc.,

Biopharma 57

Biopharma Marketing Patients Leads 57

European Pharmaceutical Review

DECEMBER 19, 2022

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. A biosimilar is a biological medicine ‘similar’ to another biological medicine already approved in the EU (the ‘reference medicine’).

Medicine 52

Medicine Biopharma Safety Food 52

pharmaphorum

OCTOBER 18, 2022

It will create a Nasdaq-listed biopharmaceutical company under the name “Oculis Holding SA”, placing Oculis in position to become a leading global ophthalmic biopharma, with product candidates to address areas of significant medical needs affecting a growing number of patient populations.

Biopharma 57

Biopharma Management Specialization Physicians 57

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.

Patients 59

Patients Pharma Education Media 59

PM360

DECEMBER 14, 2023

A New Online Destination for HCPs HealthCentral Corporation , operator of leading digital platforms that serve patients living with chronic illness, their care partners, and health professionals, has announced the newest addition to its suite of HCP support sites: MedCentral.

Physicians 52

Physicians Pharma Medical Patients 52

Pharmaceutical Technology

NOVEMBER 4, 2022

Any reduced availability of medicines has a significant impact on patient care. As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. The CMO solution.

Biopharma 52

Biopharma Manufacturing Media Pharmaceutical 52

Pharmaceutical Technology

AUGUST 10, 2022

But there are several key factors companies should consider when selecting a CMO or else potentially run the risk of supply chain failure, reputational damage, and inadequate patient safety measures to name a few. Major hurdles include not anticipating long lead times for equipment and components. Proven results??.

Biopharma 52

Biopharma Manufacturing Safety Pharmaceutical 52

pharmaphorum

DECEMBER 20, 2022

The condition is largely associated with obesity and an unhealthy diet and lifestyle, and is on the rise in industrialised nations, leading to estimates it could present a market opportunity worth tens of billions of dollars worldwide.

Pharmacology 52

Pharmacology Pharma Marketing Biopharma 52

European Pharmaceutical Review

FEBRUARY 21, 2023

They are there to do a job and ultimately to keep patients safe. This knowledge enables companies [in this sector] to accelerate drug discovery and development programmes, with a significant amount of safety, toxicity and efficacy data already known and on which we can build. What are your future predictions for the industry?

Medicine 127

Medicine Manufacturing Specialization Pharmaceutical 127

Clarivate

OCTOBER 25, 2023

The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. Impact for patients taking the diabetes drugs and blood thinners might be less noticeable since these drugs tend to receive coverage as preferred brand tiers with copays.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

JULY 20, 2023

In June 2023, an array of leading voices in AAV development for cell and gene therapies articulated the current challenges and their optimism for the rapidly advancing sector at the Cell and Gene Therapy Summit event in London. She also touched on production costs being irrecoverable—there is a high cost per patient.

Consulting 57

Consulting Side effects Manufacturing Safety 57

Clarivate

OCTOBER 19, 2023

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

MARCH 14, 2024

Research is raising concerns about PFAS use Similarly, PFAS (per- and polyfluoroalkyl substances) in pharmaceutical packaging have recently come under scrutiny, leading to significant regulatory changes. With Europe taking the lead in introducing draft regulations on PFAS, will other countries and regions implement their own regulations?

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

pharmaphorum

AUGUST 4, 2022

This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches.

Recruitment 95

Recruitment Pharma Training Pharmaceutical manufacturing 95

Pharmaceutical Technology

DECEMBER 20, 2022

Companies are recognizing the importance of working together to advance science, improve solutions, and best serve patients. Maintaining sterility is critical in the final steps of parenteral drug processing, ensuring doses are free from microbial contamination that could affect patient safety. It’s heartening.

Biopharma 52

Biopharma Manufacturing FDA Pharmaceutical 52

pharmaphorum

JANUARY 6, 2023

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Patient choice will push sponsors toward operational excellence.

Safety 107

Safety Management Patients Biopharma 107

PM360

SEPTEMBER 28, 2022

At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Now, as the President of Accord BioPharma , the U.S.

Competition 98

Competition Marketing Biopharma Manufacturing 98

PM360

JULY 13, 2023

However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. Cellectis is pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients.

Patients 98

Patients Engineering Side effects Leads 98

pharmaphorum

SEPTEMBER 12, 2022

Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. The test is conducted in a care provider’s office or our patient service centres (PSC).

Patients 102

Patients Medicine FDA Healthcare 102

pharmaphorum

SEPTEMBER 28, 2022

In recent years, the biopharma market has become progressively complex. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors. Scientific advice is a mechanism to reduce that challenge—so take it.”.

Biopharma 52

Biopharma Side effects Consulting Pharmaceutical products 52

pharmaphorum

SEPTEMBER 28, 2022

Pheon’s lead ADC PHN-010 is directed at a novel, undisclosed cancer antigen that it says is highly expressed in a broad range of solid tumours. ” The company says its ADC platform is designed to balance safety and efficacy for each target, and is already attracting interest from big pharma partners. billion in 2020.

Biopharma 52

Biopharma Pharma Leads Safety 52

European Pharmaceutical Review

DECEMBER 26, 2023

The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population. million for Hemgenix [AAV5-hFIX-Padua]). million for Hemgenix [AAV5-hFIX-Padua]).

Manufacturing 82

Manufacturing Safety Patients Competition 82

Pharmaceutical Technology

AUGUST 26, 2008

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .

Manufacturing 52

Manufacturing Pharmaceutical Biopharma Medicine 52

Clarivate

JULY 6, 2023

Precision medicine The biopharma industry is increasingly moving towards a precision medicine approach that enables patients to be treated at an earlier stage of disease for better outcomes. This process provides crucial spatial context to molecular data, enhancing our understanding of diseases and informing clinical decision-making.

Consulting 52

Consulting Medicine Biopharma Patients 52

Medgadget

MARCH 2, 2023

This leads to substantial damage to healthy tissues and too often results in poor outcomes. The rest of the patients had partial responses. with ten patients to try to duplicate the results. The goal is to irradiate the entirety of the tumor without causing much damage to healthy tissues beyond the margins.

Manufacturing 83

Manufacturing Leads Patients Medicine 83

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development. participation of white subjects.

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52